Dicerna Pharmaceuticals is a US-based biopharmaceutical company that specializes in developing treatments for liver diseases and cancers using their proprietary RNA interference technology platform. Its main development program is DCR-PH1, which aims to treat primary hyperoxaluria type 1 (PH1) and other rare inherited diseases that involve genes expressed in the liver.
Dicerna Pharmaceuticals's ticker is DRNA
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 11-50 employees working at Dicerna Pharmaceuticals
It is dicerna.com
Dicerna Pharmaceuticals is in the Healthcare sector
Dicerna Pharmaceuticals is in the Biotechnology industry
The following five companies are Dicerna Pharmaceuticals's industry peers: